Effect of ethosucximide on the reduction of neuropathic pain due to chronic constriction of the sciatic nerve in rats
Background and Aim: Neuropathic pain is caused by a lesion or disease of the peripheral or central nervous system. Since, treatment of neuropathic pains remains a challenge, the purpose of the present study was to examine the effect of ethosuximide, an anti-epileptic and relatively selective T-type...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Birjand University of Medical Sciences and Health Services
2013-05-01
|
| Series: | مجله دانشگاه علوم پزشکی بیرجند |
| Subjects: | |
| Online Access: | http://journal.bums.ac.ir/browse.php?a_code=A-10-952-1&slc_lang=en&sid=1 |
| Summary: | Background and Aim: Neuropathic pain is
caused by a lesion or disease of the peripheral or central nervous system.
Since, treatment of neuropathic pains remains a challenge, the purpose of the
present study was to examine the effect of ethosuximide, an anti-epileptic and
relatively selective T-type calcium blocker, on the behavioral responses
following chronic constriction pain (CCI) induced in rats. Materials and Methods: Experiments were performed on six groups (n=8)
of male Sprague-Dawley rats (230-280g). The groups consisted of the control
group, induced chronic constriction of the sciatic nerve (CCI), 3 groups
receiving ethosuximide with concentrations 100, 200, 300mg/kg, and one group
which received normal saline. The cold-and mechano-allodynia and thermal
hyperalgesia were measured prior to surgery (the day 0) and 3, 5, 7, 14 and 21
days postsurgery. Statistical analysis of repeated ANOVA was
used to compare the results of behavioral tests by means of SPSS software (V: 16). Results: It was found that the CCI group significantly produced mechanical
and cold allodynia and a hypersensitivity to noxious stimulations. Ethosuximide
significantly decreased cold and mechano-allodynia and thermal hyperalgesia. Conclusion: Results suggested that the CCI model significantly influences
behavioral responses to both the thermal and mechanical stimulations. Besides,
systemic administration of ethosuximide significantly decreases behavioral
responses of neuropathic pain induces through CCI. Thus, ethosuximide can be
taken as a new potential therapeutic drug used against neuropathic pain. |
|---|---|
| ISSN: | 1607-2197 2423-6152 |